Milrinone



Indications and Reactions:

Role Indications Reactions
Primary
Drug Use For Unknown Indication 37.3%
Pulmonary Hypertension 13.3%
Mean Arterial Pressure 9.6%
Hypertension 4.8%
Ventricular Dysfunction 4.8%
Ventricular Failure 4.8%
Cardiac Failure Congestive 3.6%
Heart Transplant 3.6%
Product Used For Unknown Indication 3.6%
Thrombosis 3.6%
Anticoagulant Therapy 2.4%
Cardiac Disorder 1.2%
Cardiac Failure Acute 1.2%
Cardiac Output 1.2%
Infection 1.2%
Poor Peripheral Circulation 1.2%
Spleen Disorder 1.2%
Wrong Drug Administered 1.2%
Ventricular Extrasystoles 13.6%
Atrial Fibrillation 9.1%
Death 9.1%
Device Leakage 9.1%
Intraventricular Haemorrhage Neonatal 9.1%
Allergic Myocarditis 4.5%
Cerebral Haemorrhage Neonatal 4.5%
Device Failure 4.5%
Hypertension 4.5%
Hypotension 4.5%
Overdose 4.5%
Platelet Count Decreased 4.5%
Septic Shock 4.5%
Thrombocytopenia 4.5%
Tricuspid Valve Incompetence 4.5%
Wrong Drug Administered 4.5%
Secondary
Product Used For Unknown Indication 30.2%
Pulmonary Hypertension 11.8%
Mean Arterial Pressure 9.4%
Drug Use For Unknown Indication 6.7%
Cardiac Failure 5.9%
Drug Therapy 3.9%
Cardiac Failure Chronic 3.5%
Infection 3.5%
Cardiac Failure Acute 3.1%
Nutritional Support 3.1%
Cardiomyopathy 2.4%
Pain 2.4%
Vasoconstriction 2.4%
Asthma 2.0%
Chronic Obstructive Pulmonary Disease 2.0%
Anticoagulant Therapy 1.6%
Intraoperative Care 1.6%
Pulmonary Embolism 1.6%
Sedation 1.6%
Thrombosis Prophylaxis 1.6%
Allergic Myocarditis 13.9%
Tricuspid Valve Incompetence 13.9%
Type Iv Hypersensitivity Reaction 8.3%
Death 5.6%
Intraventricular Haemorrhage Neonatal 5.6%
Overdose 5.6%
Renal Failure Chronic 5.6%
Thrombosis In Device 5.6%
Treatment Failure 5.6%
Blood Chloride Decreased 2.8%
Cardiac Fibrillation 2.8%
Drug Hypersensitivity 2.8%
Drug Interaction 2.8%
Heart Transplant 2.8%
Hyperbilirubinaemia 2.8%
Leukaemoid Reaction 2.8%
Myocarditis 2.8%
Renal Failure 2.8%
Restrictive Cardiomyopathy 2.8%
Tachycardia 2.8%
Concomitant
Product Used For Unknown Indication 60.2%
Drug Use For Unknown Indication 17.9%
Coronary Artery Bypass 5.1%
Mitral Valve Replacement 1.9%
Aortic Valve Replacement 1.6%
Cardiac Operation 1.4%
Catheterisation Cardiac 1.3%
Prophylaxis 1.3%
Mitral Valve Repair 1.1%
Acute Myeloid Leukaemia 1.0%
Sedation 0.9%
Hypertension 0.8%
Tricuspid Valve Repair 0.8%
Intra-aortic Balloon Placement 0.8%
Ventricular Assist Device Insertion 0.8%
Cardiac Failure 0.7%
Pain 0.7%
Heart Transplant 0.6%
Anaesthesia 0.6%
Cardiac Failure Congestive 0.5%
Injury 13.9%
Unevaluable Event 10.1%
Fear 8.9%
Pain 8.9%
Anxiety 8.0%
Anhedonia 7.7%
Renal Failure 6.4%
Emotional Distress 4.8%
Stress 3.9%
Renal Impairment 3.6%
Renal Failure Acute 3.0%
Ventricular Tachycardia 3.0%
Depression 2.8%
Renal Injury 2.8%
Thrombocytopenia 2.3%
Sepsis 2.1%
Thrombosis 2.1%
Multi-organ Failure 2.0%
Death 1.8%
Platelet Count Decreased 1.8%
Interacting
Maintenance Of Anaesthesia 25.0%
Pulmonary Embolism 25.0%
Induction Of Anaesthesia 16.7%
Pulmonary Hypertension 16.7%
Muscle Relaxant Therapy 8.3%
Nephroprotective Therapy 8.3%
Tumour Haemorrhage 100.0%